| Soliton, Inc., a Nasdaq listed company trading under the ticker symbol SOLY. | | | Brain and cancer is the 10th leading cause of death for men and women, killing an estimated 18,020 adults each year.
About 3,540 children will also be diagnosed with a brain tumor this year.
But because the percentage of the population affected is so small, most large pharmaceutical companies ignore treating brain tumors.
That's a big reason why icons like Senators Ted Kennedy and John McCain lost their lives to brain cancer; more specifically, glioblastoma... the most aggressive type of brain cancer..
But there could possibly be hope for patients suffering from this terrible disease with a drug called Berubicin, a brain cancer drug candidate that is preparing to enter Phase 2 clinical trials.
Click here now to see how Berbucin could combat brain cancer
Berubicin is among the first drugs of its kind that appears to actually cross the blood-brain barrier and kill brain tumor cells in cancer patients.
These brain tumor cells are simply not reachable by other therapies.
A recent milestone for the company that has licensed Berubicin from one of the largest medical institutions in the world, is that they recently received Orphan Drug designation from the FDA.
This special status may accelerate its development to treat malignant gliomas -- including glioblastoma multiforme (GBM) -- with the potential for market exclusivity upon Berubicin's approval.
Click here to learn more about Berbucin's revolutionary potential
| | 
This is a paid communication provided to customers/subscribers to DailyMarketAlerts. Although we have sent you this email, DailyMarketAlerts does NOT specifically endorse this product nor is it responsible for the content of this communication. Furthermore, we make no guarantee or warranty about what is communicated above.
|
No comments:
Post a Comment